| 多发性骨髓瘤维持治疗的研究进展 |
| |
| 引用本文： | 孔令珍,贾垂明,王 燕,刘爱春.多发性骨髓瘤维持治疗的研究进展[J].现代肿瘤医学,2018,0(15):2470-2473. |
| |
| 作者姓名： | 孔令珍 贾垂明 王 燕 刘爱春 |
| |
| 作者单位： | 哈尔滨医科大学附属肿瘤医院血液淋巴科，黑龙江 哈尔滨 150081 |
| |
| 摘 要： | 多发性骨髓瘤(multiple mfeloma,MM)是第二常见的血液肿瘤病，目前仍无法治愈。诱导治疗后序贯自体干细胞移植（ASCT）已经成为一种标准化治疗，但依然可能存在复发。使用维持治疗的目的是通过增加无进展生存期（PFS），加深缓解，进而增加总生存期(OS)。本文主要对新药时代MM的维持治疗的进展作一综述。
|
| 关 键 词： | 多发性骨髓瘤 维持治疗 沙利度胺 来那多胺 硼替佐米 |
Progress in the maintenance therapy of multiple myeloma |
| |
| Kong Lingzhen,Jia Chuiming,Wang Yan,Liu Aichun.Progress in the maintenance therapy of multiple myeloma[J].Journal of Modern Oncology,2018,0(15):2470-2473. |
| |
| Authors: | Kong Lingzhen Jia Chuiming Wang Yan Liu Aichun |
| |
| Institution: | Department of Hematology，the Harbin Medical University Cancer Hospital，Heilongjiang Harbin 150081，China. |
| |
| Abstract: | Multiple myeloma is the second most common type of blood cancer and remains incurable.Induction therapy followed by autologous transplantation has become the standard of care，but relapse still exists.The goal of using maintenance therapy has been to improve the outcomes by increasing the progression-free survival，deepening remissions and perhaps increasing overall survival.This article reviews the advances in maintenance therapy for MM in the era of novel agents. |
| |
| Keywords: | multiple myeloma maintenance therapy thalidomide lenalidomide bortezomib |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
| 点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
